Extra Arginine Meant Fewer Colon Tumors and Milder Flu in Mice
A Cell study from Rockefeller University found low arginine hides sick cells from the immune system in mice. How it works and what is still unproven.

Mice fed more arginine, a common amino acid, grew fewer colon cancer tumors and had milder influenza and SARS-CoV-2 infections, researchers at Rockefeller University report in the journal Cell. When arginine runs short, cells make less of an immune protein called MHC-I, which helps immune cells spot cancer and viruses.
The work was done in cultured cells and in mice. The authors say studies in people are still needed before anyone knows whether the effect carries over to human patients.
How arginine shortage hides sick cells
The body makes arginine on its own and also gets it from protein-rich foods. Low arginine levels have long been noted in several diseases, including colon cancer, but the reason this mattered for the body’s defenses was unclear.
MHC-I (major histocompatibility complex class I) molecules sit on the surface of cells and display small pieces of the proteins made inside. T cells, a type of immune cell, inspect those pieces. If they see fragments of a viral protein or an abnormal protein made by a tumor, they can launch an attack. This checkpoint is one part of how T cells and the rest of the immune system work.
First author Qiushuang Wu, a postdoctoral researcher in the lab of Sohail Tavazoie, looked at amino acid levels in models of colon cancer, influenza and SARS-CoV-2. Arginine was the most depleted amino acid in all of them, she said.
In lab-grown cells, Wu found 414 proteins whose levels fell abnormally when arginine was scarce. Many were already known to depend on arginine. The unexpected finding involved three genes from the HLA family, which carry instructions for MHC-I proteins.
Those proteins need arginine at many points along their chain. Without enough of it, ribosomes (the cell’s protein-building machines) stalled partway through making them. Fewer MHC-I molecules reached the cell surface, so T cells got fewer warning signals.
Arginine is also unusual in the genetic code. Six different three-letter codons in messenger RNA can call for it.
What happened in the mouse experiments
The team then changed how much arginine the animals ate. Mice on low-arginine diets developed more colon tumors, and mice on high-arginine diets developed fewer. The researchers say this points to an effect on immune recognition, beyond any change in how the cancer cells themselves behave.
Working with Heinz-Heinrich Hoffman, a research assistant professor in Charles Rice’s laboratory, Wu tested influenza and SARS-CoV-2, the virus behind COVID-19. Mice eating more arginine had milder illness. Giving extra arginine to mice after they were already infected with influenza also improved their outcomes, which Wu called “very surprising.”
In earlier work from 2023, the same group found that colon cancer cells deprived of arginine piled up more genetic mutations.
What it means, and what is still unknown
The study does not show that arginine supplements prevent or treat cancer, flu or COVID-19 in people. All of the disease results come from mice, and the cell work was done in culture.
The researchers say a moderate dose, roughly what a couple of over-the-counter tablets contain, restored MHC-I production in their experiments. Tavazoie suggests arginine could be tested in patients getting immunotherapy, cancer drugs that help the immune system find tumors, or in groups at high risk of respiratory viruses. Because arginine is cheap and easy to get, he said he hopes such trials can start soon.
Arginine levels fall with age and with poor diet. Tavazoie said that decline could help explain how colon cancer gets started and why respiratory viruses kill more older people, though the study did not test this in humans.
He also said his group is now studying whether changing other amino acids in the diet has effects in other diseases. The work was supported in part by the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University and the Weill Cancer East Hub.
Source: ScienceDaily



